| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Identification of early-onset IBD patients may enable tailored treatment and surveillance plans. With over 50 genes implicated in early-onset IBD, genetic testing should be included in the workup of children under the age of six with IBD. Join Mayo Clinic for a discussion of this testing and its clinical application.
Ann Moyer, M.D., Ph.D.
Associate Professor of Laboratory Medicine and Pathology
Division of Laboratory Genetics and Genomics
Mayo Clinic, Rochester, Minnesota
Michael Stephens, M.D.
Division Chair, Pediatrics Gastroenterology and Hepatology
Department of Pediatric Gastroenterology
Mayo Clinic, Rochester, Minnesota
Upon completion of this activity, participants should be able to:
Clinicians who see IBD patients: gastroenterologists, hepatologists, primary care internal medicine, family medicine, nurse practitioners, physician assistants, laboratory directors, lab supervisors, and laboratory sendout managers.
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
Contact us: mcleducation@mayo.edu
